Fig. 1.

Patient disposition in the health-related quality of life population. CNS central nervous system, cSCC cutaneous squamous cell carcinoma, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, ECOG PS Eastern Cooperative Oncology Group performance status, EQ-5D-5L European Quality of Life 5-Dimension 5-Level, RECIST v1.1 Response Evaluation Criteria in Solid Tumours version 1.1. ^aParticipants may have been excluded for more than one reason. Reasons not listed included no metastatic disease or previously treated locally recurrent disease (n = 2), another histologic type of skin cancer other than invasive squamous cell carcinoma as the primary disease (n = 2), diagnosed with and/or treated for additional malignancy within the past 5 years (n = 2), known active central nervous system metastases and/or carcinomatous meningitis (n = 2), no histologically confirmed cSCC as the primary site of malignancy (n = 1), not willing to provide informed consent (n = 1), history of (non-infectious) pneumonitis that required treatment with steroids or had current pneumonitis (n = 1), and another inclusion/exclusion criterion that prevented enrolment in the study (n = 1). ^bClinical progression was defined as worsening of clinical status with or without radiographic progression of disease. ^cProgressive disease was defined as radiographically diagnosed disease progression per RECIST v1.1 criteria